Key Highlights

● MDCX shares fell 36.39% to $0.10 in Thursday’s October 8 session, extending a long decline.

● Medicus Pharma shares drifted from above a dollar early in 2026 to about ten cents.

● The Nasdaq Composite fell 1.25% to near 27,193 on a semiconductor and AI infrastructure selloff.

Medicus Pharma (NASDAQ:MDCX) was among the heaviest decliners on the US market during the Thursday, October 8, 2026 session, closing at $0.10 after falling 36.39% on the day. A price near ten cents invites the question of whether the figure is a data error, but the level is consistent with the stock’s trajectory rather than anomalous. Price history shows Medicus Pharma drifting steadily lower through 2026, from above a dollar early in the year into the low tens of cents by the autumn, so a print near ten cents in early October fits a well-established downtrend.

A Prolonged, Multi-Month Erosion

No announcement specific to October 8 is confirmed. What the record indicates is a prolonged, multi-month erosion in the share price, the kind of pattern typically associated with a cash-consuming clinical-stage company that has had to raise Capital repeatedly and has seen its Equity steadily diluted and de-rated. Against that backdrop, a further sharp drop on a given session does not require fresh company-specific news to make sense.

Dilution Pressure and Low-Float Dynamics

For a nano-cap biotechnology name that has already fallen this far, the most plausible explanation for Thursday’s move is a combination of dilution pressure and low-float dynamics. When a stock trades in pennies, the bid-ask spread and the limited depth of the order book mean that even ordinary selling can translate into a large percentage decline. Overhang from prior financings, the conversion of warrants or other instruments, and the simple absence of buyers willing to step in can all produce an outsized one-day drop. No documentation confirms a single discrete catalyst.

A Risk-Off Session Offers No Relief

The broader market offered no relief for speculative, lightly capitalized stocks. Thursday’s session carried a risk-off tone centered on technology. The Nasdaq Composite fell 1.25% to close near 27,193, pressured by a selloff in semiconductor and artificial-intelligence-infrastructure names after a report cast doubt on the Revenue outlook for a leading AI company. The S&P 500 slipped 0.47% to roughly 7,765, while the Dow Jones Industrial Average rose 0.10% to about 51,232 on energy and defensive strength. In sessions where investors retreat from risk, the most fragile small-cap and nano-cap stocks tend to absorb the most damage.

Rates Compound the Difficulty

Interest rates compound the difficulty. The ten-year Treasury Yield held near 5.3% to 5.35%, close to multidecade highs, with Federal Reserve minutes reinforcing a hawkish stance. For a pre-profit biotechnology company, elevated yields raise the discount applied to distant potential cash flows and make any future capital raise both costlier and more dilutive, which keeps structural pressure on a stock already trading in pennies.

A Deeply Depressed Biotech Keeps Sliding

Medicus Pharma traded on Thursday as a deeply depressed nano-cap biotech tends to trade during a cautious session, extending a decline that has been underway for months. The percentage drop is real, and the price near ten cents is consistent with that months-long slide, with dilution and low-float dynamics the mechanics most consistent with the move in the absence of a verified announcement.